Genethera Logo


At every level of business development, we anticipate a significant jump in business value. Each milestone achieved will incrementally bump market valuation thus creating liquidity. Further, while we simultaneously track competitors, we also track possible acquirers. If we can demonstrate our technology and ability to scale quickly, we believe that the company will be a viable candidate for a merger or acquisition. We anticipate that an exit will occur between 3-5 years.

        Liquidity will be driven by increased market valuation over the years.

        We currently have brokerage firms that will underwrite GeneThera for both the OTC and later AMEX.

        Potential international market offerings will drive valuation.

Access our latest filings on the U.S. Securities and Exchange Commission website.  

Download the 3rd Quarter 2011 XBRL filings here.

Read more about the GeneThera management team.

If you have any questions or would like to learn more about GeneThera investment opportunities, please call 303-439-2085
or email